ATG5 and melanoma: Interestingly, it is shown that heterozygous (but not homozygous) Atg5 loss compromised the response of BRAF inhibitors in melanoma-specific mouse models, raising caution about the incomplete blockade of this gene in clinical aspects, since this may cause an unexpected worsening of patient outcomes [53].